Lineage Cell Therapeutics Inc (LCTX)

[Cincinnatus]

I'm wondering if anyone else is considering another source of "near term value generating" that might appear in 2018.

If you notice slide 9 of the latest AgeX presentation, it mentions Renelon as a "repurposed drug." The significant entry there might be the mention of the 510(K) Clearance.

I believe Patrick Cox mentioned a while back that the repurposed drug was already FDA approved and if they can get a 510(K) device approval from the FDA, it often takes very little time.

The "scarless healing" category seems possibly purposely ambiguous. If this FDA approved drug has some relationship to the COX7A1 gene as described in the presentation's ending slides, they could be going after a variety of major markets with a 510(K) timeline.

Just a hope and a dream right now, but there are some tea leaves out there that could settle in just the right configuration if we're lucky. Flying under the radar now, but leaving a very tantalizing trail.